Background Infants with hyperammonemia can present with nonspecific findings so ordering an ammonia level requires a high index of suspicion. Renal replacement therapy (RRT) should be considered for ammonia concentrations of >400 μmol/L since medical therapy will not rapidly clear ammonia. However, the optimal RRT prescription for neonatal hyperammonemia remains unknown. Hemodialysis and continuous renal replacement therapy (CRRT) are both effective, with differing risks and benefits. Case-diagnosis/treatment We present the cases of two neonates with hyperammonemia who were later diagnosed with ornithine transcarbamylase deficiency and received highdose CRRT. Using dialysis/replacement flow rates of 8,000 mL/h/1.73 m 2 (1,000 mL/h or fourfold higher than the typical rate used for acute kidney injury) the ammonia decreased to <400 μmol/L within 3 h of initiating CRRT and to <100 μmol/L within 10 h. Conclusions We propose a CRRT treatment algorithm to rapidly decrease the ammonia level using collaboration between the emergency department and departments of genetics, critical care, surgery/interventional radiology, and nephrology.
Introduction
Infants with hyperammonemia present with lethargy, hypotonia, and tachypnea [1] . Ammonia levels of >150 μmol/L necessitate further diagnostic evaluation [2] . Worse outcome is associated with persistently elevated ammonia (>800 μmol/L) for >24 h or prolonged coma [3] [4] [5] . Prompt treatment is critical to rapidly clear ammonia and minimize morbidity [2, 6] .
Renal replacement therapy (RRT), including intermittent hemodialysis (HD) or continuous renal replacement therapy (CRRT), is considered to be a treatment option for ammonia concentrations of >400 μmol/L [1, 6, 7] . However, the optimal RRT prescription remains unknown. Intermittent HD achieves small molecule clearance with diffusion and removes ammonia more rapidly than a standard CRRT prescription used for acute kidney injury of 2,000 mL/h/1.73 m 2 [4] . CRRT employs diffusive and/or convective mechanisms and is traditionally favored in hemodynamically unstable, volumeoverloaded patients. While hyperammonemic infants are not volume overloaded, we speculated that CRRT would be the preferred treatment modality due to the high risks of hemodynamic instability from the underlying metabolic disorder, small patient size, and use of drugs that increase nitric oxide release (arginine) and lower systemic pressure [8] . In these patients with normal kidney function, CRRT also allows for easier management of potassium and phosphorus.
We present two cases of ornithine transcarbamylase deficiency where the ammonia decreased rapidly using highdose CRRT. We discuss the risks and benefits of both extracorporeal RRT modalities and present a standardized CRRT practice algorithm to improve outcomes for these rare, yet complex situations. [9] . Citrate anticoagulation was started at 50 % of the normal rate due to concern for decreased hepatic metabolism [4] . Prior to CRRT, the ammonia had peaked at 1,454 μmol/L. After 2 h of RRT, the ammonia had decreased to 367 μmol/L (Fig. 1) . CRRT was discontinued after 10 h (ammonia 92 μmol/L) with a peak rebound level to 149 μmol/L. The clinical course was complicated by femoral artery thrombosis with compartment syndrome requiring fasciotomy. Although his long-term neurologic outcome is unknown, he regained spontaneous movements 1 h after CRRT initiation.
Case 2
A 6-day-old male infant (3.7 kg) presented with poor feeding, vomiting, and somnolence. On arrival, he was hypothermic with profound tachypnea. The laboratory test results showed a normal complete blood count, venous pH of 7.48, iCa of 2.58 mEq/L, a serum bicarbonate of 23 mEq/L, and a creatinine of 0.6 mg/dL. A septic work-up was initiated and on NICU admission, his ammonia level (drawn 7 h after presentation) was 776 μmol/L. Intravenous arginine, sodium phenylacetate, and sodium benzoate were started.
A right internal jugular 7.5 Fr. dialysis catheter was placed surgically, and high-dose continuous veno-venous hemodiafiltration was initiated 15 h after presentation with a Prismaflex™ M60 filter. Prismasate™ (Gambro Renal Products) dialysate contained 4 mEq/L potassium, 32 mEq/L 0  1000  2  367  1  814  4  227  3  398  6  178  6  183  8  118  8  91  10 92 -- Fig. 1 In our two patients, the continuous renal replacement therapy (CRRT) prescription produced clearance comparable to that of hemodialysis (HD), without significant ammonia rebound, hypotension, or electrolyte abnormalities. The actual decrease in ammonia concentration in both patents (cases 1 and 2; both treated with high-dose CRRT) is compared to the theoretical clearance over time that can be achieved with intermittent HD. The theoretical HD clearance was based on a blood flow of 30 mL/min, an initial ammonia level of 1,200 μmol/L, a patient weight of 3 kg (total body water 0.6 mL/kg), and an ammonia clearance of−natural log (concentration at time X/concentration at time zero). Because in case 2, the first circuit clotted after 45 min due to mechanical obstruction of the RRT catheter, we illustrate the decrease in ammonia after the start of the second circuit. We assumed that the initial ammonia level was 1,000 μmol/L based on the last exact value (1,043 μmol/L) 1 h prior to initiation of the second circuit (the ammonia level 15 min before the start of the second circuit was reported to be >1,000 μmol/L as the laboratory did not dilute the sample to obtain the exact concentration). In both cases, the ammonia fell to <200 μmol/L within 6 h of CRRT initiation bicarbonate, and 2 mEq/L sodium phosphate. The blood flow was 40 mL/min, dialysate flow was 900 mL/h, and replacement flow was 100 mL/h for a total of 1,000 mL/h (7,700 mL/h/1.73 m 2 ). The ammonia prior to CRRT was 1,387 μmol/L. A red blood cell prime was used with bicarbonate to help prevent bradykinin release syndrome [9] . The first circuit with heparin anticoagulation clotted due to a mechanical catheter obstruction 45 min after initiation and was restarted using full-dose citrate anticoagulation (ammonia level remained >1,000 μmol/L prior to restart; Fig. 1 ). Seven hours later, the ammonia level had dropped to 90 μmol/L and the second circuit was stopped due to a grade I intraventricular hemorrhage. Over the next 10 h, without further RRT, the patient's ammonia peaked at 402 μmol/L, but remained <100 μmol/L over the next 24 h with continuation of medical therapy. The patient underwent liver transplantation 6 months later and currently is thriving.
Discussion
Neonatal hyperammonemia requires prompt intervention to reduce neurological damage. Decreasing ammonia production by reversing catabolism is extremely important. Pharmacological management with sodium phenylacetate and sodium benzoate in conjunction with arginine and full caloric support may improve survival [6] .
When the ammonia is significantly elevated (>400 μmol/L), RRT is needed to achieve rapid clearance [1] . RRT with HD or CRRT can achieve ammonia clearance even alone or in combination with medical therapy. However, the optimal dose or preferred modality remains poorly defined. CRRT may decrease ammonia rebound compared to shortduration, intermittent HD due to the continuous nature of the therapy [2] . CRRT may offer additional advantages over HD, such as electrolyte replacement that can be safely mixed in the dialysate/replacement fluid by pharmacy to maintain normal phosphorus and potassium levels.
In patients treated initially with HD for inherited metabolic disorders, dialysate rates of 500 mL/min have successfully reduced toxin levels [10] , but many patients require additional CRRT for metabolite rebound [1, 11] . McBryde et al. [11] speculated that initial HD treatment may improve outcomes compared to CRRT, but they also noted a high risk of ammonia rebound in patients treated initially with HD. Furthermore, their CRRT clearance rates (2,000 mL/h/1.73 m 2 ) were only 25 % of those used in our patients. Using CRRT as the initial therapy may avoid the risk of treatment delays from switching dialysis modalities. However, CRRT is not without risks, including the bradykinin release syndrome seen especially with AN 69-membranes [9] . This risk can be lowered by normalizing the pH of the blood prime in the circuit [9] . To quickly decrease the ammonia level, collaboration between the emergency department and the departments of genetics, critical care, surgery/interventional radiology, and nephrology is essential. We recommend checking a serum ammonia level in infants presenting with unexplained lethargy, hypotonia, apnea, or seizures. An ammonia level of >150 μmol/L should prompt emergent consultation with the departments of genetics/metabolism and critical care. If RRT is needed, the departments of general surgery/interventional radiology and nephrology should be consulted. The patient should be emergently transferred to an institution with the capability and expertise to perform RRT and place neonatal vascular access. The ultimate choice of RRT modality (HD vs. CRRT) depends on the expertise and availability of specific resources at the treating institution. Medical management should begin immediately to prevent further increases in the ammonia level. However, since pharmacological therapy is commonly known to take more than 24 h to effectively control ammonia, dialysis planning should begin at ammonia levels of >400 μmol/L.
For RRT initiation, a 7 Fr. double-lumen right internal jugular dialysis catheter should be inserted, and 5 Fr. catheters should be avoided [12] . We recommend a CRRT blood flow of 30-50 mL/min with citrate anticoagulation dosed at half the usual rate (0.75 mL/h × the blood flow in mL/min) to account for decreased hepatic metabolism, precluding the need for systemic heparinization [9] . No net fluid should be removed, and dialysate/replacement fluid should contain 4 mEq/L of potassium and 2 mEq/L of phosphate, adjusted to the patient's electrolytes. During CRRT, iCa (patient and circuit), serum electrolytes, platelets, and ammonia should be monitored every 1-2 h [1] . CRRT should continue until the ammonia level is 100-200 μmol/L [2] .
To the best of our knowledge, only two studies have rigorously assessed the clearance characteristics of extracorporeal therapy in neonates, both with maple syrup urine disease [10, 13] . Our in vivo data supports the rapid ammonia clearance that can be achieved with high-dose CRRT (Fig. 1) . Our patients had a rapid decrease in ammonia using high-dose CRRT with a dialysis/replacement flow rate of 8,000 mL/h/1.73 m 2 (1,000 mL/h), which is fourfold higher than flows used to manage acute kidney injury [9] and other inborn errors of metabolism [10] . We selected the CRRT dose based on small solute clearance calculations to match the clearance predicted with intermittent HD (Fig. 1) . With intermittent HD, clearance is limited by blood flow rates. In our model, assuming a blood flow of 30 mL/min (which is well tolerated by most infants) would result in a small solute clearance of 1,800 mL/hr with HD. This is comparable to the clearance we observed in our patients treated with CRRT (1,000 mL/h).
Others studies have suggested CRRT clearance rates of 5 L/h without validating the recommendations [2, 9] . We believe CRRT clearance rates of 100-600 mL/h [4, 14, 15] are less effective because of the time necessary to decrease the ammonia level [4] .
Although controlled trials do not exist, a prospective study has demonstrated that slower reductions in ammonia levels may worsen long-term outcomes [5] . We support the initial use of high-flow CRRT to rapidly clear ammonia, decrease rebound, safely replace electrolytes, eliminate the need for modality switching, and limit further hemodynamic instability. While our patients did have a small rebound in ammonia after CRRT was stopped, neither patient required subsequent RRT. Further study is warranted to see if even higher CRRT rates may be beneficial to more closely mimic the rapid clearance that can be achieved with HD.
